Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

CONSOLIDATED STATEMENTS OF CASH FLOWS (Additional information)

v3.22.1
CONSOLIDATED STATEMENTS OF CASH FLOWS (Additional information)
₪ in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2021
CAD ($)
Disclosure Of Detailed Information About Additional Cash Flow Information [Line Items]  
Acquisition of subsidiary $ 12,536
Trichome Financial Corp. (“Trichome”) [Member]  
Disclosure Of Detailed Information About Additional Cash Flow Information [Line Items]  
Working capital (excluding cash and cash equivalents) 9,427
Investments 319
Investments 0
Inventories 3,883
Property, plant and equipment 15,193
Right of use assets 15,037
Lease liability (15,037)
Intangible assets 6,458
Goodwill 67,269
Non-controlling interest 0
Long term loans 0
Bank Loans 0
Deferred tax liability 0
Common shares issued upon the acquisition (99,028)
Identifiable assets acquired (liabilities assumed) (362)
Panaxia Logistics Ltd. [Member]  
Disclosure Of Detailed Information About Additional Cash Flow Information [Line Items]  
Accrued purchase consideration liability (126)
Investments 0
Investments 2,837
Inventories 19
Property, plant and equipment 88
Right of use assets 0
Lease liability 0
Intangible assets 776
Goodwill 3,240
Non-controlling interest 0
Long term loans 0
Bank Loans 0
Deferred tax liability 0
Common shares issued upon the acquisition (6,960)
Identifiable assets acquired (liabilities assumed) 6,834
MYM Nutraceuticals Inc. (“MYM”) [Member]  
Disclosure Of Detailed Information About Additional Cash Flow Information [Line Items]  
Working capital (excluding cash and cash equivalents) 4,471
Loans payable (915)
Property, plant and equipment and right of use assets 6,735
Investments 0
Investments 0
Inventories 4,180
Property, plant and equipment 6,105
Right of use assets 630
Lease liability (873)
Intangible assets 17,200
Goodwill 39,932
Non-controlling interest 0
Long term loans 0
Bank Loans (915)
Deferred tax liability (4,061)
Common shares issued upon the acquisition (62,620)
Identifiable assets acquired (liabilities assumed) (131)
Vironna pharmacy [Member]  
Disclosure Of Detailed Information About Additional Cash Flow Information [Line Items]  
Working capital (excluding cash and cash equivalents) 44
Accrued purchase consideration liability (1,855)
Property, plant and equipment and right of use assets 210
Investments 0
Investments 0
Inventories 639
Property, plant and equipment 210
Right of use assets 0
Lease liability 0
Intangible assets 2,316
Goodwill 2,250
Non-controlling interest (1,026)
Long term loans 0
Bank Loans 0
Deferred tax liability (532)
Common shares issued upon the acquisition (3,319)
Identifiable assets acquired (liabilities assumed) 1,407
Pharm Yarok pharmacy [Member]  
Disclosure Of Detailed Information About Additional Cash Flow Information [Line Items]  
Working capital (excluding cash and cash equivalents) (646)
Accrued purchase consideration liability (1,332)
Investments 0
Investments 0
Inventories 346
Property, plant and equipment 1,145
Right of use assets 0
Lease liability 0
Intangible assets 974
Goodwill 4,294
Non-controlling interest 0
Long term loans (1,042)
Bank Loans 0
Deferred tax liability (224)
Common shares issued upon the acquisition (4,606)
Identifiable assets acquired (liabilities assumed) 3,169
Oranim pharmacy [Member]  
Disclosure Of Detailed Information About Additional Cash Flow Information [Line Items]  
Working capital (excluding cash and cash equivalents) 595
Accrued purchase consideration liability (2,726)
Property, plant and equipment and right of use assets 389
Investments 0
Investments 0
Inventories 1,043
Property, plant and equipment 389
Right of use assets 1,312
Lease liability (1,312)
Intangible assets 2,991
Goodwill 2,907
Non-controlling interest (1,849)
Long term loans 0
Bank Loans 0
Deferred tax liability (688)
Common shares issued upon the acquisition (4,830)
Identifiable assets acquired (liabilities assumed) $ 1,619